Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth CHP Formulary Coverage & PA Update | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy N/A

    EmblemHealth 2026 Formulary (CHP) — Prescription Drug Formulary and Utilization Management

    Customize your policy alerts

    Sign up for all EmblemHealth policy alerts

    Know when EmblemHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the EmblemHealth 2026 formulary listing covered prescription drugs, tiers, and utilization management indicators (e.g., PA, QL, ST, SP) that govern pharmacy benefits for affected EmblemHealth plan members.

    Policy Summary
    PayerEmblemHealth
    PolicyEmblemHealth 2026 Formulary (CHP) — Prescription Drug Formulary and Utilization Management
    Policy CodePolicy N/A
    Change TypeAdministrative update — formulary effective date confirmed
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization (PA) when a drug entry shows 'PA' before dispensing to ensure coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-06-01formulary effective date
    150+distinct entries (excerpt)
    PA/QL/ST/SPutilization flags present
    Availablemail-order/home delivery
    Multiplespecialty agents flagged

    Formulary Coverage Criteria

    General formulary coverage conditions

    Covered when ALL of the following are met

    Formulary inclusion and benefit rules: Drug is listed on the plan formulary and subject to any indicated utilization management flags (e.g., PA, QL, ST, SP, LA, FF, ACA, OTC).

    Members should check their Certificate of Coverage for plan-specific benefits; providers must obtain prior authorization when 'PA' is indicated to avoid denial.

    Listed product coverage with requirements

    Coverage indicated by listing with tier and associated requirement codes

    Listed drugs require adherence to stated requirements: Each product is shown with a Drug Tier and may include requirement/limit codes (examples: ACA, PA, QL, LA, SP, ST, FF, OTC). Coverage is contingent on meeting those requirements shown on the formulary line item.see per-product Requirements/Limits

    No additional clinical PA criteria are provided in these listing chunks; follow per-product PA/QL/LA/SP rules.

    Policy Summary
    PayerEmblemHealth
    PolicyEmblemHealth 2026 Formulary (CHP) — Prescription Drug Formulary and Utilization Management
    Policy CodePolicy N/A
    Change TypeAdministrative update — formulary effective date confirmed
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization (PA) when a drug entry shows 'PA' before dispensing to ensure coverage.
    SourceLink
    On This Page
    Formulary Coverage CriteriaCoding and Code ListsProvider Requirements and AuthorizationStep Therapy Indicators and Starter PacksQuantity Limits by ProductSpecialty, Limited Access, and Site-of-Care FlagsAbbreviations and DefinitionsBackground and ScopeBiosimilar Listings

    Formulary entries and flags

    Formulary coverage with product-specific requirement flags

    Formulary entry requirements: Coverage for each listed drug is subject to the requirement/limit flags shown alongside the product (examples include PA, QL, LA, SP, ACA, OTC, FF, ST).per-product Requirements/Limits

    Providers must follow the indicated management controls (e.g., obtain PA when 'PA' shown; respect numeric QL). Specific clinical authorization criteria are maintained in the payer's PA program documents.

    Covered when Tier listed and any PA/QL/LA/SP requirements are met

    Coverage and requirements within these chunks are presented as product listings with associated flags; coverage is conditional based on the listed Requirement/Limits fields.

    Formulary coverage conditions: Drug is on formulary (commonly assigned a Drug Tier) AND when Requirements/Limits includes PA, QL, LA, SP or ST the member/provider must satisfy those constraints for coverage.see per-product Requirements/Limits (e.g., numeric QL values shown)

    Examples in these chunks include numeric QL values and PA/LA/SP flags; follow the listed per-product limits and authorization processes.

    General coverage conditional on utilization management

    Covered when product-specific formulary requirements are met

    General coverage condition: Drug is on formulary AND any indicated utilization management flags (PA, QL, LA, SP, ST, FF, ACA, OTC) are satisfied per the formulary line item.

    Per-item PA and QL values (e.g., REPATHA QL 6 syringes/28 days; NEXLETOL PA, QL 30 tablets/30 days) must be followed; documentation should be provided with PA requests as required.

    Coverage with utilization controls

    Coverage and utilization controls are indicated per product; coverage may be conditional on PA, LA, QL, SP, FF, ACA, OTC, or ST flags.

    Examples of conditional coverage: Examples from the formulary: NUCALA — LA, PA, QL (3 pens/28 days), SP; TRIKAFTA — LA, PA, QL (56 packets/28 days to 90 tablets/30 days); CIMZIA — PA, QL (4 syringes/28 days), SP; FOSRENOL — QL (packs/30 days), ST; many products also list ACA or OTC designations.per-product QL values as listed

    These are illustrative examples from the formulary showing how coverage depends on the listed flags and numeric limits.

    Coverage conditioned on formulary controls

    Coverage and utilization controls as listed (PA, QL, LA, SP) — coverage is conditional per these controls

    Formulary control requirements: Drugs flagged with 'PA' require prior authorization before coverage; drugs with 'QL' are limited to the specified quantities; 'SP' indicates specialty pharmacy dispensing; 'LA' denotes limited access or restricted site-of-care; 'ST' indicates step therapy where applicable.see each line item for exact QL values (e.g., 1 pen/28 days, 540 mLs/30 days, 30 tablets/30 days)

    Starter/titration packs and specialty distribution requirements are shown on product lines; providers must comply with these controls and submit supporting documentation when required.

    This formulary listing does not guarantee coverage for every plan member. Not all drugs in the list are paid for by all drug benefit plans; members and providers must consult the member's Certificate of Coverage or benefit schedule to confirm whether a specific product is covered, applicable copay/coinsurance, and any plan-specific rules. The Certificate of Coverage and member portal at my.emblemhealth.com provide plan-specific coverage details and contact information for benefit questions.

    Within the extracted formulary segments there are no standalone exclusion conditions listed. The document presents product lines with requirements/limits flags (e.g., PA, QL, LA, SP) that control coverage and access, but it does not state explicit exclusion rules in these chunks. Providers should assume coverage is conditional on meeting any indicated requirement rather than on an explicit item-level exclusion shown here.

    The sections reviewed do not contain clinical exclusion statements. Contraceptive products are frequently identified with an ACA designation and some items show an OTC designation, but the extract does not list clinical exclusions that render a drug non‑covered for medical reasons. Coverage remains subject to the plan's general rules and any product-specific requirement flags.

    No explicit exclusion lists are provided in this segment of the formulary. Entries present drug names, tiers, and requirement/limit indicators but do not specify products that are categorically excluded from coverage in the chunks reviewed.

    This portion of the formulary shows product listings with associated requirement flags (e.g., PA, QL) but contains no explicit statements excluding particular products from coverage. Any access restrictions shown are implemented via those flags rather than explicit product exclusions in this excerpt.

    No explicit exclusion language appears in these chunks. The extract functions as a formulary listing with utilization management indicators rather than a section enumerating excluded products.

    This segment does not present any full product exclusion statements. Several over‑the‑counter (OTC) or ACA‑designated items (for example, acetaminophen, aspirin, and nicotine replacement products) are listed as covered with OTC or ACA flags; however, the extract does not identify items that are categorically excluded from coverage.

    The reviewed extract does not include language declaring any drug to be not medically necessary. Coverage determinations in these chunks are conveyed through listing status and requirement/limit flags (PA, QL, ST, SP, LA), not through explicit "not medically necessary" statements.

    Within these extracted chunks there are no explicit statements that certain therapies are "not medically necessary." Products are presented with formulary tiering and utilization management indicators; absence of an explicit NMN determination means clinical eligibility is controlled by the listed requirement flags and the member's benefit rules.

    No explicit "not medically necessary" rules are contained in this excerpt. The policy fragments show per‑product flags (for example PA and QL) which drive coverage evaluation rather than NMN declarations in these chunks.

    This portion of the formulary does not list items as "not medically necessary." Instead, coverage may be conditioned on utilization management controls such as Prior Authorization (PA), Quantity Limits (QL), Limited Access (LA), Specialty Pharmacy (SP), or Step Therapy (ST). Failure to satisfy those controls may result in non‑coverage, but the extract does not state NMN determinations explicitly.

    No explicit determinations of "not medically necessary" are indicated in this extract. The document instead flags products with access controls (e.g., PA, QL, LA, SP) and notes that these controls govern coverage decisions for the listed items.

    Coding and Code Lists

    Formulary drug listings (examples)mixedCovered
    amoxicillin (trihydrate) cap 250 mg, 500 mgamoxicillin (trihydrate) cap 250 mg, 500 mg
    amoxicillin (trihydrate) tab 500 mg, 875 mgamoxicillin (trihydrate) tab 500 mg, 875 mg
    amoxicillin & k clavulanate tab 250-125 mg, 500-125 mg, 875-125 mgamoxicillin & k clavulanate tab 250-125 mg, 500-125 mg, 875-125 mg
    cefuroxime axetil tab 250 mg, 500 mgcefuroxime axetil tab 250 mg, 500 mg
    azithromycin tab 250 mg; 500 mgazithromycin tab 250 mg (Zithromax z-pak); azithromycin tab 500 mg (Zithromax)
    clarithromycin tab 250 mg, 500 mgclarithromycin tab 250 mg, 500 mg
    fidaxomicin tab 200 mg (Dificid)fidaxomicin tab 200 mg (Dificid)
    doxycycline hyclate cap 50 mg, 100 mgdoxycycline hyclate cap 50 mg, 100 mg
    ciprofloxacin hcl tab 250 mg, 500 mg, 750 mgciprofloxacin hcl tab 250 mg (base equiv), 500 mg (base equiv), 750 mg (base equiv)
    levofloxacin tab 250 mg, 500 mg, 750 mglevofloxacin tab 250 mg, 500 mg, 750 mg
    1–10 of 12
    1/2
    NDC/CPT/HCPCS not providedmixed
    No codes listed
    Vaccines / Passive immunizing agents / Palforziamixed
    ADACELtet tox-diph-acell pertuss ad inj 5-2-15.5 lf-lf-mcg/0.5ml
    BOOSTRIXtet-diph-acell pertuss ad pref syr 5-2.5-18.5 lf-mcg/0.5ml
    DAPTACELdiph, acellular pert & tet tox inj 15 lf-23 mcg-5 lf/0.5ml
    INFANRIXdiph, acellular pert & tet tox inj 25 lf-58 mcg-10 lf/0.5ml
    KINRIXdiph-tetanus-acell pert-polio, ipv vacc susp pref syr 0.5 ml
    PEDIARIXdiph-tet tox-acell pert-hep b-polio ipv vac susp pref syr
    PENTACELdiph-ac per-tet tox ad-poliov-haemoph b poly vac for im susp
    QUADRACELdiph-tetanus tox ad-acell pert & polio virus, ipv vac inj
    TENIVACtetanus-diphtheria toxoids (td) inj 5-2 lf/0.5ml
    VAXELISdiph-tet tox-ac pert ad-polio ipv-hib-hep b rec susp pre syr
    1–10 of 13
    1/2
    Antineoplastics / targeted oncology / specialty oral agentsmixed
    abiraterone acetate 250 mgZytiga
    abiraterone acetate 500 mgZytiga
    ALECENSAalectinib hcl cap 150 mg
    ALUNBRIGbrigatinib (various strengths)
    AYVAKITavapritinib (25-300 mg)
    BOSULIFbosutinib (various strengths)
    BRAFTOVIencorafenib cap 75 mg
    BRUKINSAzanubrutinib (80 mg cap; 160 mg tab)
    CABOMETYXcabozantinib s-malate (20/40/60 mg)
    CAPRELSAvandetanib tab (100 mg, 300 mg)
    1–10 of 28
    1/3
    Listed specialty/oncology drugs and requirementsmixed
    KOSELUGO - selumetinib sulfate cap 10 mgListed with Drug Tier = 1; Requirements/Limits = LA, PA, QL (63 tablets/28 days), SP
    KOSELUGO - selumetinib sulfate cap 25 mgDrug Tier = 1; Requirements/Limits = LA, PA, QL (120 capsules/30 days), SP
    KRAZATI - adagrasib tab 200 mgDrug Tier = 1; Requirements/Limits = LA, PA, QL (180 tablets/30 days), SP
    LENVIMA (various daily dose packs)Multiple therapy pack strengths listed with Drug Tier = 1; Requirements/Limits include LA, PA, QL (various capsules/30 days), SP
    LUPRON DEPOT (1-,3-,4-,6-month)Leuprolide acetate injectables listed as Drug Tier = 1; Requirements/Limits = SP
    LONSURF - trifluridine-tipiracil (15-6.14 mg, 20-8.19 mg)Drug Tier = 1; Requirements/Limits = LA, PA, QL (60-80 tablets/28 days), SP
    LORBRENA - lorlatinib (25 mg, 100 mg)Drug Tier = 1; Requirements/Limits = LA, PA, QL (30-120 tablets/30 days), SP
    LYNPARZA - olaparib (100 mg, 150 mg)Drug Tier = 1; Requirements/Limits = LA, PA, QL (120 tablets/30 days), SP
    MEKINIST - trametinib (bottle and tablet strengths)Drug Tier = 1; Requirements/Limits = PA, QL (13 bottles/28 days or tablet QL), SP
    NINLARO - ixazomib citrate cap (2.3, 3, 4 mg)Drug Tier = 1; Requirements/Limits = LA, PA, QL (3 capsules/28 days), SP
    1–10 of 20
    1/2
    Requirement/Limit Codes present in entriesmixed
    PAPrior Authorization
    QLQuantity Limit
    LALimited Access
    SPSpecialty Pharmacy
    FFFormulary flag (FF) — listing shows FF for one selinexor pack
    ACAAffordable Care Act — contraceptive coverage designation
    OTCOver-the-counter
    Listed drug products and formulationsmixed
    NP THYROID 90thyroid tab 90 mg (1 1/2 grain)
    RENTHYROIDthyroid tab various strengths (15 mg to 120 mg)
    SYNTHROIDlevothyroxine sodium tab 25 mcg–300 mcg
    THYQUIDITYlevothyroxine sodium oral solution 100 mcg/5ml
    TIROSINTlevothyroxine sodium cap various strengths
    ACTHARcorticotropin inj gel 80 unit/ml
    carglumic acid (Carbaglu)soluble tab 200 mg
    cinacalcet (Sensipar)tab 30 mg, 60 mg, 90 mg
    GALAFOLDmigalastat hcl cap 123 mg
    GENOTROPIN / OMNITROPE / SKYTROFAsomatropin products (various cartridges and strengths)
    1–10 of 18
    1/2
    Selected product strengths/formulations notedmixed
    140 mg/mlREPATHA - evolocumab subcutaneous soln prefilled syringe 140 mg/ml
    140 mg/mlREPATHA SURECLICK - evolocumab subcutaneous soln auto-injector 140 mg/ml
    180 mgNEXLETOL - bempedoic acid tab 180 mg
    180-10 mgNEXLIZET - bempedoic acid-ezetimibe tab 180-10 mg
    Furosemide formulationsmixedCovered
    80 mg/10mlFUROSCIX - furosemide subcutaneous cartridge kit 80 mg/10ml
    10 mg/mlFUROSEMIDE - furosemide oral soln 10 mg/ml
    Drug listing (no billing codes provided)mixed
    N/AThis segment lists NDC-level products and strength forms but does not list CPT/HCPCS/ICD-10 codes.
    Formulary product entries (no billing codes listed)mixed
    N/AThis excerpt lists drug products and formulary flags; no CPT/HCPCS/ICD-10/NDC codes are provided in these chunks.
    Drug list entriesNDC | mixed
    No codes listed
    Drug listing (no billing codes in this excerpt)mixed
    N/AThis part contains drug names, strengths and formulary flags but no CPT/HCPCS/ICD-10/NDC codes in these chunks.
    Formulary entries (no CPT/HCPCS/ICD-10 codes provided in this segment)mixed
    No codes listed
    inv-35: Quantity limits examples — per-product examples
    Example QL — oncology/oral agents120 tablets/30 days (example: LYNPARZA, other oral oncology agents)
    Example QL — alternate oncology strength60 tablets/30 days (example: abiraterone 500 mg listing)
    Example QL — capsules90 capsules/30 days (examples appear for various oral oncology/capsule formulations)
    Most actionable QL pattern120 tablets/30 days — commonly used as the monthly tablet limit for many oral agents
    inv-36: Common QL examples
    Common QL — 30/3030 tablets/30 days (common maintenance tablet QL)
    Common QL — 60/3060 tablets/30 days (common 1–2 month supply limit for some agents)
    Common QL — 84/2884 tablets/28 days (therapy-pack / 28-day capsule examples)
    Most actionable common QL30 tablets/30 days — frequently used as standard monthly QL for many chronic oral medications
    inv-37: Quantity limits examples — GALAFOLD, IMCIVREE, JYNARQUE
    GALAFOLD QL14 capsules/28 days
    IMCIVREE QL10 vials/30 days
    JYNARQUE QL56 tablets/28 days OR 60 tablets/30 days depending on pack
    ContextThese QLs are product-specific for orphan/specialty agents with pack-dependent limits
    inv-38: Tablet QL example
    Tablet QL example210 tablets/30 days
    ContextUsed as an upper monthly tablet dispensing limit for multiple oral cardiovascular and other chronic agents
    inv-39: Propranolol oral solution QL examples
    Propranolol oral solution 40 mg/5 mL2400 mLs/30 days
    Propranolol oral solution 20 mg/5 mL4800 mLs/30 days
    NoteTwo solution strengths listed with distinct monthly mL quantity limits
    inv-40: REPATHA QL — 6 syringes/28 days
    REPATHA QL (general)6 syringes/28 days
    Formulation-specific notePrefilled syringe presentation listed as 140 mg/mL with QL = 6 syringes/28 days
    inv-41: REPATHA quantity limit — 6 syringes/28 days
    REPATHA QL (prefilled syringe)6 syringes/28 days
    REPATHA (summary) — actionable6 syringes/28 days — supplier must adhere to this monthly syringe limit for coverage
    Related formulationREPATHA listed as evolocumab 140 mg/mL in formulary entries
    inv-42: REPATHA SURECLICK quantity limit — 6 pens/28 days
    REPATHA SURECLICK QL6 pens/28 days
    Product detailSureClick auto-injector presentation (evolocumab 140 mg/mL) limited to 6 pens per 28 days

    Provider Requirements and Authorization

    Note

    Prior Authorization and utilization flags

    Certain drugs in the formulary are subject to utilization management flags. When a product line lists initials such as PA, QL, ST, SP, LA or FF after the drug name, the provider must follow the associated process (e.g., obtain prior authorization, adhere to quantity limits, enroll in specialty program, or observe site-of-care restrictions) before the plan will pay for the drug.

    • PA = Prior Authorization; QL = Quantity Limit; ST = Step Therapy; SP = Specialty; LA = Limited Availability; FF = Frozen Formulary
    Prior Authorization

    Prior authorization required for select specialty antivirals/antifungals

    Prior authorization is required for many specialty antivirals and antifungals. Examples in the formulary include CRESEMBA, EPCLUSA, HARVONI, SOFOSBUVIR-containing products, and VOSEVI — each shows PA (and often QL and SP) in the Requirements/Limits field.

    • CRESEMBA — Requirements/Limits = PA (chunk 21)
    • EPCLUSA / SOFOSBUVIR-containing products — Requirements/Limits = PA, QL, SP (chunks 34, 37)
    • HARVONI — Requirements/Limits = PA, QL, SP (chunk 28)
    Prior Authorization

    Prior authorization and ACA preventive coverage

    Entries marked with ACA (and many vaccines) indicate Affordable Care Act preventive coverage, but where PA is listed next to a medication (e.g., VOSEVI) providers must still obtain prior authorization per the Requirements/Limits shown on the formulary line.

    • VOSEVI — Requirements/Limits = PA, QL, SP (chunk 37)
    • Multiple vaccine/passive immunizing agent entries are marked ACA (chunks 56)
    Prior Authorization

    Prior authorization and limits

    Many products are listed with PA and may also include quantity limits (QL), limited access (LA), or specialty (SP) designations; providers must obtain PA and respect QL/LA/SP constraints as indicated on each line.

    • abiraterone examples show PA and QL (chunk 60)
    • Itraconazole oral solution shows PA and QL (chunk 22)
    Prior Authorization

    Prior authorization required when PA listed

    When a formulary entry shows 'PA' in the Requirements/Limits field, the provider must obtain prior authorization before the plan will cover the drug. Many specialty and oncology agents on the list include PA, QL, and SP flags.

    • KOSELUGO, KRAZATI, LENVIMA entries include PA and QL (chunk 72)
    • ROMVIMZA, ROZLYTREK examples list PA, QL, SP (chunk 83)
    • XTANDI, ZEJULA entries show PA and QL (chunk 91)
    Prior Authorization

    Prior authorization and limit flags

    Formulary entries often combine PA with limit flags (QL, SP, LA); providers must follow the specified authorization and quantity rules for those products to avoid claim denials.

    • Selinexor (XPOVIO) therapy packs list FF, PA, QL and SP (chunk 90)
    • REPATHA and other biologics list explicit QL alongside PA/SP (chunk 162)
    Prior Authorization

    PA required for selected GLP-1 / incretin agents

    Prior authorization is required for many GLP‑1 and incretin agents as indicated by 'PA' in their entries. Examples include MOUNJARO, OZEMPIC, RYBELSUS and TRULICITY where PA and QL are shown.

    • MOUNJARO — Requirements/Limits = PA, QL (chunk 111)
    • OZEMPIC — Requirements/Limits = PA, QL (chunk 111)
    • TRULICITY and RYBELSUS are shown with PA/QL in adjacent sections (chunks 111,115)
    Prior Authorization

    Prior authorization and specialty program required

    Many specialty endocrine/metabolic and high‑cost agents require both prior authorization and enrollment in a specialty program (SP) or specialty distribution channel before coverage will be approved.

    • ACTHAR and other endocrine agents list LA, PA, SP (chunk 128)
    • GALAFOLD, IMCIVREE show LA, PA, QL and SP (chunk 130)
    Prior Authorization

    PA required for listed PA or LA/SP products

    Prior authorization is required for products explicitly marked 'PA' and for many products with LA or SP flags; providers must obtain PA when 'PA' appears in the Requirements/Limits field (examples include FUROSCIX, NEXLETOL/NEXLIZET, VASCEPA).

    • FUROSCIX — LA, PA, QL (8 kits/180 days) (chunk 157)
    • NEXLETOL / NEXLIZET — PA, QL (30 tablets/30 days) (chunk 162)
    • VASCEPA — PA, QL (chunk 163)
    Prior Authorization

    Prior authorization required where PA listed

    Many formulary lines simply indicate 'PA' next to the product name; the provider is responsible for obtaining prior authorization for any drug that shows 'PA' before coverage will be provided.

    • NEXLETOL/NEXLIZET examples show PA required (chunk 162)
    Documentation Required

    Examples: biologic PA and QL

    Some biologic and specialty injectables list specific quantity limits in addition to PA (for example, REPATHA shows QL = 6 syringes/28 days); providers must request authorization consistent with those QL values.

    • REPATHA prefilled syringe — QL 6 syringes/28 days (chunk 167)
    • REPATHA SURECLICK — QL 6 pens/28 days (chunk 167)
    Prior Authorization

    Prior authorization required for multiple specialty agents

    Prior authorization is required for numerous specialty immunologic and respiratory biologics and injectables; the formulary lists NUCALA, TEZSPIRE, XOLAIR, ALYFTREK and others with LA/PA/QL/SP flags — obtain PA and follow site‑of‑care and QL rules.

    • NUCALA — LA, PA, QL (3 pens/28 days), SP (chunk 180)
    • XOLAIR — LA, PA, SP (chunk 183)
    • ALYFTREK — LA, PA, QL (chunk 183)
    • CIMZIA, ENTYVIO PEN examples appear with PA, QL, SP (chunk 199)
    Prior Authorization

    Prior authorization requirement

    Many specialty or higher‑cost products (e.g., CIMZIA, ENTYVIO PEN, GATTEX, SKYRIZI, TREMFYA, ZYMFENTRA) require prior authorization and may also include QL, LA, SP or ST restrictions; providers must secure PA and comply with those limits.

    • CIMZIA — PA, QL (4 syringes/28 days) (chunk 199)
    • ENTYVIO PEN — LA, PA, QL (2 pens/28 days) (chunk 199)
    • GATTEX — LA, PA, SP (chunk 200)
    • SKYRIZI — PA, QL (1 pen/56 days) (chunk 203)
    Prior Authorization

    Prior authorization required for specified products

    Certain specified products are designated PA on the formulary (e.g., tasimelteon / Hetlioz capsules and oral suspension); providers must obtain prior authorization for these formulations when shown as PA.

    • Tasimelteon (Hetlioz) capsule and suspension — Requirements/Limits = PA, QL (30 capsules/30 days) (chunk 232)
    Prior Authorization

    Prior authorization required for specific listed drugs

    Several listed drugs (including SUNOSI, AUSTEDO/AUSTEDO XR and many MS disease‑modifying therapies) show 'PA' in their Requirements/Limits; obtain PA before dispensing to ensure coverage.

    • SUNOSI — PA, QL (30 tablets/30 days) (chunk 238)
    • AUSTEDO / AUSTEDO XR — PA, QL, SP (chunks 238–239)
    • MS agents (e.g., KESIMPTA) — PA, QL, SP (chunk 244)
    Prior Authorization

    Prior authorization required for specified agents

    Many specialty agents and certain opioid/controlled products are listed with 'PA' and QL requirements (examples include BELBUCA, fentanyl patches, hydromorphone ER); providers must obtain PA and adhere to QL for these agents to avoid noncoverage.

    • BELBUCA and buprenorphine products — PA/QL noted (chunk 254)
    • Fentanyl transdermal patches — PA, QL (15 patches/30 days) (chunk 255)
    • Hydrocodone ER and morphine ER entries show PA, QL (chunks 255, 258–261)
    • Multiple biologics (adalimumab variants, ENBREL) require PA, QL, SP (chunks 262–265)
    Step Therapy

    Step Therapy overview

    Step therapy (ST) is used for some products and requires trial of specified preferred drugs before the plan will cover alternatives; providers can request exceptions per plan process.

    • ST = Step Therapy as defined in the formulary abbreviations (chunk 8)
    • Examples of products flagged ST appear elsewhere in the listing (multiple chunks)
    Note

    Step therapy not present in this segment

    This extract does not include explicit step‑failure sequences or detailed step therapy protocols for particular drugs; where 'ST' appears it indicates a step requirement but the specific sequence is not listed in this segment.

    • No explicit step therapy sequences are provided in these chunks (chunk 37)
    Documentation Required

    PALFORZIA level packaging

    PALFORZIA is listed in multiple level packs (initial, titration, maintenance) with LA and SP flags; providers should follow the product-level pack designations and any PA/LA/SP rules when initiating and continuing therapy.

    • PALFORZIA levels (Initial, Level 0–11, Titration, Maintenance) all list LA and SP (chunks 56–57)
    Step Therapy

    Step therapy flags

    Some products in the formulary are flagged with ST (step therapy); for example KERENDIA is shown with an 'ST' indicator — providers should verify step requirements before submitting PA requests.

    • KERENDIA is flagged ST in the endocrine/metabolic listing (chunk 130)
    Note

    Utilization Management Indicators

    The formulary uses requirement flags (PA, QL, ST, SP) after drug names to indicate utilization management. Providers must check the Requirements/Limits shown on each drug line and follow the indicated processes prior to dispensing.

    • Flags appear after drug names to indicate PA, QL, ST, SP, LA, FF (chunks 6, 8)
    Documentation Required

    Prior authorization/documentation requirement

    When a drug entry includes 'PA' or 'SP', providers must submit the plan‑required prior authorization request and any supporting clinical documentation per EmblemHealth procedures to secure coverage.

    • Example: itraconazole oral solution requires PA and QL (chunk 22)
    Documentation Required

    Documentation for PA

    Quantity limits (QL) shown for many agents define the maximum covered dispensing (e.g., tablets/30 days, mL/30 days). Providers and pharmacies must adhere to QL and include appropriate documentation when requesting quantities above the listed limit.

    • Examples: GALAFOLD QL 14 capsules/28 days; ITRACONAZOLE QL 120 capsules/30 days (chunks 130, 22)
    Documentation Required

    Prior Authorization required when PA listed

    Products listed with PA and/or QL require review and prescriber documentation supporting the clinical indication and dosing schedule; include such documentation with PA requests to facilitate approval.

    • abiraterone entries show PA and QL (chunk 60)
    Documentation Required

    PA/LA/SP/QL requirements present

    When PA or QL is listed for a product, the provider must submit prior authorization documentation or adhere to the stated quantity limits as specified on the formulary line to avoid claim denial.

    • MOUNJARO and OZEMPIC entries list PA and QL with specified pen/tablet QLs (chunk 111)
    Denial Risk

    Failure to meet listed requirements may trigger denial

    If required prior authorization is not obtained or quantity limits/site restrictions (LA/SP) are not met, the plan may deny coverage or the claim at the point of adjudication.

    • Not obtaining required PA may result in noncoverage (chunk 6)
    • Drugs marked PA/LA/SP/QL may trigger denial if requirements aren’t met (chunk 19)
    Denial Risk

    Prior authorization indicated

    Entries marked 'PA' (for example, MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY) indicate prior authorization is required; failure to obtain PA may cause denial of coverage.

    • MOUNJARO, OZEMPIC examples show PA and QL on their form lines (chunk 111)
    Note

    OTC-designated products

    Some insulin products are marked 'OTC' in the listing (e.g., certain Humulin/Novolin formulations); OTC designation can affect coverage pathways — verify member benefit details before dispensing.

    • OTC designation appears for some insulin-related entries (chunk 115–116)
    Denial Risk

    Quantity limits and PA may trigger denial

    Requests that exceed the listed quantity limits or that do not include required prior authorization are at risk for denial; providers should confirm QL values and include supporting rationale when requesting larger quantities.

    • Examples: tablet QL 210 tablets/30 days for some oral agents (chunk 144)
    • FUROSCIX QL 8 kits/180 days (chunk 157)
    Prior Authorization

    PA/QL/LA/SP trigger utilization management

    Products listed with PA, QL, LA or SP flags are subject to utilization management — providers must obtain required authorizations, comply with quantity limits, and route dispensing through specialty pharmacy when indicated.

    • NEXLETOL/NEXLIZET require PA and QL (chunk 162)
    • CIMZIA and ENTYVIO PEN list PA, QL, SP (chunk 199)
    • NUCALA lists LA, PA, QL, SP (chunk 180)
    Note
    Note

    Step Therapy Indicators and Starter Packs

    Step therapy overviewNotes / examples
    Step therapy (ST) may require trying specified preferred drugs first before coverage of alternatives
    Exceptions may be requested; see PA/appeals processes
    Agent class / examplesFormulary controls noted
    HCV agents (e.g., HARVONI, SOVALDI, SOFOSBUVIR/VELPATASVIR) and HIV regimens (e.g., GENVOYA, STRIBILD, ISENTRESS)
    Many are listed with PA and QL and some with SP/LA; specific entries show PA, QL (e.g., HARVONI PA, QL 28 packets/28 days; VOSEVI PA, QL 28 tablets/28 days)
    Explicit step sequences present?Source note
    No — this extract does not list explicit multi-step failure sequences
    Formulary shows flags (PA, QL, SP, LA, ST) but not the step-by-step prior-failure criteria in these chunks
    ProductPackaging / implication
    PALFORZIA
    Multiple level/pack configurations listed (initial, titration, maintenance) implying staged dosing program; Requirements/Limits = LA, SP
    Agent / pack formatFormulary note
    selinexor (XPOVIO) therapy packs (80 mg; 20 mg packs)
    Therapy pack formats and QL shown (e.g., 4 tablets/28 days; 24 tablets/28 days; 32 tablets/28 days) — no explicit step-failure sequencing provided
    Agent group / examplesFormulary controls
    Selected GLP-1 / GLP/GIP agents (examples: MOUNJARO, OZEMPIC, TRULICITY)
    These are marked PA and have QL values (e.g., MOUNJARO PA, QL 4 pens/28 or 180 days; OZEMPIC PA, QL 1–3 pens/28 days) — step therapy specifics not detailed here
    ProductST flag noted
    KERENDIA (finerenone)
    Flagged with 'ST' in the listing indicating potential step therapy requirement
    Presence of step sequencesFormulary context
    No explicit step therapy steps listed in these chunks
    Entries predominantly show utilization flags (PA, QL, LA, SP) rather than detailed step criteria
    Agents with access controlsComment
    Multiple agents listed with PA, QL, LA that may function as access controls
    The document does not provide explicit step sequences — these controls may act as alternative utilization management mechanisms
    ProductST indicator / notes
    ferric citrate (Auryxia) 1 gm
    Requirements/Limits include ST (step therapy), FF, and QL (360 tablets/30 days)
    StatementExamples / implication
    Some products are designated 'ST' (step therapy)
    Listings (e.g., FOSRENOL shows ST; other entries note ST in Requirements/Limits) indicate these products will require trial/failure of alternatives per the payer's step program before approval
    Examples of products with ST or titration packsFormulary listing notes
    Fetzima (levomilnacipran) — includes ST and titration pack entries
    Fanapt (iloperidone) titration packs, Trintellix and other antidepressants/hypnotics listed with ST or starter/titration pack QL values — Requirements/Limits include QL and ST where shown
    Starter / titration kits notedExamples
    Starter/titration packs and starter kits are listed for multiple agents
    Examples include MAVENCLAD, MAYZENT, ZEPOSIA starter kits and other therapy packs (e.g., ZEPOSIA starter kit QL and PA shown) — these imply required induction/titration regimens prior to full dispensing
    Class / examplesStep therapy flag
    Certain NSAIDs / analgesics (examples: KETOPROFEN ER, MECLOFENAMATE SODIUM)
    Designated 'ST' in Requirements/Limits indicating step therapy applies before preferred alternatives are covered

    Quantity Limits by Product

    inv-164: ARIKAYCE - amikacin sulfate liposome inhal susp 590 mg/8.4ml — 28 vials
    ARIKAYCE (amikacin liposome inhalation)28 vials/28 days
    ContextListed with Requirements/Limits = LA, PA, QL, SP for the inhalation suspension 590 mg/8.4 mL
    inv-165: ARIKAYCE — 28 vials
    ARIKAYCE (summary line)28 vials/28 days
    RequirementsLA, PA, QL (28 vials/28 days), SP
    inv-166: ITRACONAZOLE capsules — 120 capsules
    Itraconazole capsules120 capsules/30 days
    NotesOral solution also listed with PA and a larger mL QL (1200 mLs/30 days)
    inv-167: Various antivirals — 28/30/84 tablet examples
    Antivirals — common packet/tablet QLs28 tablets/28 days (e.g., SOVALDI/EPCLUSA/VOSEVI pellet/tab presentations)
    Monthly tablet QL examples30 tablets/30 days (e.g., GENVOYA, other combos) and 84 tablets/28 days (e.g., MAVYRET) depending on product)
    Most actionable summary28 tablets/28 days or 30 tablets/30 days — typical antiviral QLs for direct-acting HCV agents
    inv-168: Various (TRIUMEQ PD, VOSEVI, XOFLUZA, zidovudine) — mixed examples
    Examples across products180 tablets/30 days; 28 tablets/28 days; 1920 mL/30 days — varies by drug and formulation (e.g., TRIUMEQ PD, zidovudine syrup)
    ContextEntries include both high-count tablet QLs and large-volume liquid QLs depending on formulation
    inv-169: abiraterone acetate — 120 tablets/30 days (250 mg) or 60 tablets/30 days (500 mg)
    Abiraterone acetate (250 mg)120 tablets/30 days
    Abiraterone acetate (500 mg)60 tablets/30 days
    Actionable noteDifferent strengths have distinct QLs — ensure correct strength QL applied for coverage
    inv-170: COMETRIQ (cabozantinib kits) — 1 carton/28 days
    COMETRIQ (cabozantinib kit)1 carton/28 days
    NotesListed as cabozantinib kit with LA, PA, QL and SP flags
    inv-171: GOMEKLI (mirdametinib) — 168 tablets/28 days (1 mg)
    GOMEKLI (mirdametinib) 1 mg168 tablets/28 days
    ContextTherapy pack/strength-specific QL for specialty oral agent
    inv-172: ALUNBRIG — 30 tablets/180 days (initiation) or 120 tablets/30 days
    ALUNBRIG initiation pack30 tablets/180 days (initiation pack)
    ALUNBRIG maintenance120 tablets/30 days (30 mg)
    NoteDifferent pack and maintenance QLs shown for ALUNBRIG
    inv-173: Example entries (multiple drugs) — varied QLs
    Examples — assorted QLs63 tablets/28 days; 120 capsules/30 days; 84 tablets/28 days; 30 tablets/30 days — varies by drug
    GuidanceCheck per-line item QL for the exact product and pack presentation
    inv-174: selinexor tab therapy pack 80 mg — 4 tablets/28 days
    Selinexor therapy pack 80 mg4 tablets/28 days
    Most actionable selinexor pack4 tablets/28 days — therapy-pack-specific QL for once-weekly 80 mg pack
    inv-175: selinexor tab therapy pack 20 mg (60 mg twice weekly) — 24 tablets/28 days
    Selinexor 20 mg (60 mg twice weekly pack)24 tablets/28 days
    Use notePack-specific QL reflects dosing schedule (60 mg twice weekly)
    inv-176: selinexor tab therapy pack 20 mg (80 mg twice weekly) — 32 tablets/28 days
    Selinexor 20 mg (80 mg twice weekly pack)32 tablets/28 days
    Dosing notePack QL aligns with twice-weekly 80 mg total weekly dosing
    inv-177: enzalutamide (XTANDI) 40 mg — 120 capsules/30 days
    Enzalutamide (XTANDI) 40 mg120 capsules/30 days or 120 tablets/30 days
    Most actionable XTANDI QL120 capsules/tablets per 30 days — standard monthly limit for 40 mg presentation
    inv-178: enzalutamide (XTANDI) 80 mg — 60 tablets/30 days
    Enzalutamide (XTANDI) 80 mg60 tablets/30 days
    NoteHigher-strength tablet has lower tablet-count QL reflecting dosing
    inv-179: abiraterone acetate (YONSA) — 120 tablets/30 days
    YONSA (abiraterone micronized)120 tablets/30 days
    ContextListed with LA, PA, QL and SP flags for specialty oral oncology use
    inv-180: niraparib (ZEJULA) — 30 tablets/30 days
    ZEJULA (niraparib)30 tablets/30 days
    NoteStandard monthly tablet QL for this PARP inhibitor
    inv-181: vemurafenib (ZELBORAF) — 240 tablets/30 days
    ZELBORAF (vemurafenib)240 tablets/30 days
    ContextHigh-count monthly tablet QL for specific oncology regimens
    inv-182: vorinostat (ZOLINZA) — 120 capsules/30 days
    ZOLINZA (vorinostat)120 capsules/30 days
    ContextMonthly capsule QL for this HDAC inhibitor
    inv-183: idelalisib (ZYDELIG) — 60 tablets/30 days
    ZYDELIG (idelalisib)60 tablets/30 days
    NoteStandard monthly tablet QL for this specialty oral agent
    inv-184: testosterone td gel 25 mg/2.5 gm — 60 packets/30 days
    Testosterone td gel 25 mg/2.5 gm60 packets/30 days
    Use noteTopical gel packet QL for testosterone replacement
    inv-185: testosterone td gel 12.5 mg/act — 4 bottles/30 days
    Testosterone td gel 12.5 mg/act4 bottles/30 days
    ContextMetered‑dose pump/bottle presentation has a lower bottle-count QL
    inv-186: COMBIPATCH estradiol-norethindrone patch — 8 patches/28 days
    COMBIPATCH (estradiol-norethindrone)8 patches/28 days
    ContextPatch QL expressed per 28-day cycle
    inv-187: CLIMARA PRO patch — 4 patches/28 days
    CLIMARA PRO patch4 patches/28 days
    NoteWeekly patch schedules summarized as a 28-day QL
    inv-188: EVAMIST estradiol transdermal spray — 5 bottles/93 days
    EVAMIST spray5 bottles/93 days
    ContextExtended-day QL (93-day) shown for transdermal spray presentation
    inv-189: estradiol td gel (Divigel) packets — 30 packets/30 days
    Divigel estradiol TD gel packets30 packets/30 days
    NoteStandard monthly packet QL for Divigel topical gel
    inv-190: dapagliflozin (Farxiga) 5 mg, 10 mg — 30 tablets/30 days
    Dapagliflozin (Farxiga) 5 mg, 10 mg30 tablets/30 days
    GLYXAMBI (empagliflozin-linagliptin)30 tablets/30 days
    inv-191: GLYXAMBI (empagliflozin-linagliptin) — 30 tablets/30 days
    GLYXAMBI30 tablets/30 days
    ContextCommon monthly tablet QL for combined SGLT2/DPP agents
    inv-192: dapagliflozin (Farxiga) — 30 tablets
    Farxiga standard QL30 tablets (30 days)
    NoteShort-term QL shown per formulary line — verify plan-specific dispensing intervals
    inv-193: JANUMET — 60 tablets
    JANUMET QL60 tablets/30 days
    NoteStandard combined DPP4-metformin tablet QL
    inv-194: MOUNJARO (certain strengths) — 4 pens/180 days or 4 pens/28 days depending on strength
    MOUNJARO (certain strengths)4 pens/180 days OR 4 pens/28 days depending on strength
    ActionApply strength-specific QL when processing prior authorization or pharmacy claims
    inv-195: OZEMPIC (pens/tablets varied) — 1-3 pens/28 days or tablet QL (30/180 days)
    OZEMPIC pens — QL1–3 pens/28 days depending on pen strength
    OZEMPIC tablets — QL30 tablets/180 days (oral formulation) or 30 tablets/30 days depending on tablet strength/presentation
    inv-196: FIASP (vials/pens/cartridges) — multi-presentation QLs
    FIASP vials10 vials/30 days
    FIASP pens33 pens/30 days
    FIASP cartridges100 mL/30 days
    inv-197: HUMALOG (cartridges/pens/vials) — 33 cartridges/pens or 100 mL/30 days
    HUMALOG cartridges/pens QL33 cartridges/pens/30 days
    HUMALOG vials QL100 mL/30 days
    inv-198: INSULIN GLARGINE-YFGN / SEMGLEE — 33 pens/30 days or 10 vials/30 days
    INSULIN GLARGINE-YFGN / SEMGLEE pens33 pens/30 days
    INSULIN GLARGINE-YFGN / SEMGLEE vials10 vials/30 days
    inv-199: GALAFOLD — 14 capsules
    GALAFOLD14 capsules/28 days
    RequirementsLA, PA, QL; specialty agent packaging-specific limit
    inv-200: IMCIVREE — 10 vials
    IMCIVREE10 vials/30 days
    ContextListed with LA, PA, QL and SP flags
    inv-201: JYNARQUE — 56 tablets / 28 days OR 60 tablets / 30 days depending on pack
    JYNARQUE pack-dependent QL56 tablets/28 days OR 60 tablets/30 days depending on pack
    NoteApply correct pack QL when adjudicating claims
    inv-202: TERIPARATIDE (Forteo) — 1 pen
    TERIPARATIDE (Forteo)1 pen/28 days
    VOXZOGO30 vials/30 days
    inv-203: VOXZOGO — 30 vials
    VOXZOGO30 vials/30 days
    ContextSpecialty pediatric biologic with monthly vial QL
    inv-204: Various oral cardiovascular agents — 210 tablets
    Oral cardiovascular agents (example QL)210 tablets/30 days (common monthly tablet cap across many CV agents)
    ContextUsed for digoxin, many beta blockers and related agents as listed
    inv-205: multiple oral tablets — 210
    Multiple oral tablets QL (beta blockers etc.)210 tablets/30 days
    Applies tometoprolol, nadolol, nebivolol, pindolol, and many class members as listed
    inv-206: propranolol hcl oral solution 40 mg/5ml — 2400
    Propranolol oral solution 40 mg/5 mL2400 mLs/30 days
    Propranolol oral solution 20 mg/5 mL4800 mLs/30 days
    NoteTwo strengths have separate monthly mL QLs
    inv-207: propranolol hcl oral solution 20 mg/5ml — 4800
    Propranolol 20 mg/5 mL solution4800 mLs/30 days
    ContextHigher mL QL for lower-concentration solution
    inv-208: FUROSCIX - furosemide subcutaneous cartridge kit 80 mg/10ml — 8 kits
    FUROSCIX (furosemide subcutaneous kit)8 kits/180 days
    NoteListed with LA, PA, QL and specialty flags — QL given over 180 days
    inv-209: NEXLETOL / NEXLIZET — 30
    NEXLETOL / NEXLIZET QL30 tablets/30 days
    RequirementPA and QL noted for NEXLETOL/NEXLIZET entries
    inv-210: REPATHA (evolocumab) — 6
    REPATHA (evolocumab) QL summary6 syringes or 6 pens per 28 days depending on presentation
    Prefilled syringe detail140 mg/mL prefilled syringe — 6 syringes/28 days
    inv-211: VASCEPA — 240 capsules/30 days (0.5 g) or 120 capsules/30 days (1 g)
    VASCEPA 0.5 g QL240 capsules/30 days
    VASCEPA 1 g QL120 capsules/30 days
    RequirementPA and QL flags present for VASCEPA formulations
    inv-212: REPATHA prefilled syringe 140 mg/ml — 6 syringes
    REPATHA prefilled syringe (140 mg/mL)6 syringes/28 days
    ReferenceListed explicitly in formulary with QL 6 syringes/28 days
    inv-213: REPATHA SURECLICK auto-injector 140 mg/ml — 6 pens
    REPATHA SURECLICK auto-injector (140 mg/mL)6 pens/28 days
    NotePen presentation QL equals 6 pens/28 days as listed
    inv-214: VASCEPA 0.5 g capsules — 240 capsules
    VASCEPA 0.5 g capsules240 capsules/30 days
    VASCEPA 1 g capsules120 capsules/30 days
    inv-215: VASCEPA 1 g capsules — 120 capsules
    VASCEPA 1 g capsules120 capsules/30 days
    ContextLower capsule count per month for higher‑dose capsule formulation
    inv-216: ivabradine tab (Corlanor) — 60 tablets
    Ivabradine (Corlanor)60 tablets/30 days
    NoteStandard monthly tablet QL for this specialty CV agent
    inv-217: TYVASO inhalation solution 0.6 mg/ml — 7 packages
    TYVASO inhalation solution (0.6 mg/mL)7 packages/28 days
    TYVASO DPI maintenance cartridges112 cartridges/28 days
    inv-218: TYVASO DPI maintenance cartridges — 112 cartridges
    TYVASO DPI maintenance cartridges (kit)112 cartridges/28 days
    NoteLarge cartridge QLs reflect inhalation device refill requirements
    inv-219: NUCALA - mepolizumab auto-injector 100 mg/ml — 3 pens
    NUCALA auto-injector 100 mg/mL3 pens/28 days
    NUCALA prefilled syringe 40 mg/0.4 mL1 syringe/28 days
    inv-220: NUCALA - mepolizumab pref syringe 40 mg/0.4ml — 1 syringe
    NUCALA prefilled syringe (40 mg/0.4 mL)1 syringe/28 days
    ContextDifferent presentations have distinct QLs
    inv-221: TRIKAFTA — 56 packets/28 days to 90 tablets/30 days depending on presentation
    TRIKAFTA (pack presentations)56 packets/28 days to 90 tablets/30 days depending on presentation
    ActionApply QL matching the submitted pack/tablet presentation for claims
    inv-222: pirfenidone — various QL entries
    Pirfenidone examples21 tablets/180 days; 180 capsules/30 days; 90 tablets/30 days — varies by product form
    ContextMultiple QLs listed for different pack sizes and presentations
    inv-223: CIMZIA - certolizumab pegol — 4 syringes/28 days; starter kit 1 kit/180 days
    CIMZIA (certolizumab) QL4 syringes/28 days; starter kit 1 kit/180 days
    ContextPrefilled syringe kit and starter-kit QLs specified
    inv-224: ENTYVIO PEN - vedolizumab auto-injector 108 mg/0.68ml — 2 pens/28 days
    ENTYVIO PEN2 pens/28 days
    FormulationVedolizumab auto-injector 108 mg/0.68 mL listed with LA, PA, QL and SP
    inv-225: CIMZIA — 4 syringes
    CIMZIA (summary) — QL4 syringes/28 days
    Related entriesStarter kit shown as 1 kit/180 days
    inv-226: FOSRENOL (examples) — 180 packs / 30 days; 120 packs / 30 days
    FOSRENOL examples180 packs/30 days or 120 packs/30 days depending on pack
    NotePhosphate binder pack QLs vary by presentation
    inv-227: TREMFYA — 1 syringe / 28 days
    TREMFYA1 syringe/28 days
    ContextMonthly injectable QL for guselkumab listed as 1 syringe/28 days
    inv-228: ZYMFENTRA — 2 pens / 28 days
    ZYMFENTRA2 pens/28 days
    NotesInfliximab-dyyb auto-injector pen QL shown per 28-day period
    inv-229: desvenlafaxine succinate tab er 100 mg — 120 tablets
    Desvenlafaxine ER 100 mg120 tablets/30 days
    ContextStandard monthly QL for extended-release antidepressant
    inv-230: escitalopram 5 mg tab — 120 tablets
    Escitalopram 5 mg120 tablets/30 days
    NoteCommon SSRI monthly tablet QL
    inv-231: Fetzima (various strengths) — 30 capsules
    Fetzima (levomilnacipran) QL30 capsules/30 days
    ST flagListed with ST for selected formulations — check step edits
    inv-232: clozapine orally disintegrating tabs — 90-270 tablets depending on strength
    Clozapine ODT QL range90–270 tablets/30 days depending on strength
    Operational noteDose-strength dependent QLs — ensure correct strength adjudication
    inv-233: suvorexant (Belsomra) — 30 tablets
    Suvorexant (Belsomra)30 tablets/30 days
    ContextStandard monthly insomnia agent QL
    inv-234: amphetamine-dextroamphetamine formulations — 30 to 360 tablets/capsules range
    Amphetamine-dextroamphetamine formulationsRanges from 30 to 360 tablets/capsules depending on formulation
    GuidanceExtended-release vs immediate-release and pack type determine QL — verify specific formulation line
    inv-235: atomoxetine hcl cap 25 mg — QL 120 capsules/30 days
    Atomoxetine 25 mg capQL 120 capsules/30 days
    NoteHigher-count monthly QL for certain ADHD agents
    inv-236: methylphenidate hcl soln 5 mg/5ml (Methylin) — QL 450 mls/30 days
    Methylphenidate (Methylin) oral solution 5 mg/5 mLQL 450 mLs/30 days
    ContextLiquid stimulant QL substantially larger in volume than tablets — apply per formulation
    inv-237: KESIMPTA - ofatumumab auto-injector — QL 1 pen/28 days
    KESIMPTA (ofatumumab) QL1 pen/28 days
    ContextAuto-injector monthly QL for MS therapy
    inv-238: sodium oxybate oral solution (Xyrem / XYWAV) — QL 540 mls/30 days
    Sodium oxybate (XYWAV/ Xyrem) QL540 mLs/30 days
    NoteHigh-volume oral solution QL for sleep-disorder therapies
    inv-239: BELBUCA buccal films — 60 films
    BELBUCA buccal films60 films/30 days
    ContextBuccal opioid film QL listed per month
    inv-240: fentanyl transdermal patches 72 hr — 15 patches
    Fentanyl transdermal patch 72 hr15 patches/30 days
    Opioid QL/PA noteMany opioid/patch products also flagged PA and QL — follow opioid management rules

    Specialty, Limited Access, and Site-of-Care Flags

    Billing Rule

    specialty pharmacy

    Drugs designated 'SP' require specialty pharmacy distribution; providers should ensure prescriptions for SP‑flagged biologics and complex therapies are routed to the specialty pharmacy and that PA documentation is submitted.

    • KESIMPTA, KESIMPTA QL/PA listed (chunk 244)
    • Multiple adalimumab biosimilars and reference products list PA, QL, SP (chunks 262–263)
    Documentation Required

    specialty

    Several agents are flagged 'SP' indicating specialty pharmacy dispensing is required or preferred; prescribers must coordinate specialty distribution and any required PA with the specialty pharmacy.

    • VOSEVI shows SP in its Requirements/Limits (chunk 37)
    • Formulary notes many products with SP designation (chunk 245)
    Documentation Required

    infusion center

    Many specialty agents are marked 'LA' (limited access) for site‑of‑care restrictions such as infusion center or limited dispensing sites; providers must follow LA instructions and obtain any required PA for administration at approved sites.

    • LA flags appear on oncology and specialty injectables (chunks 246, 247)
    • Entries marked LA indicate site‑of‑care or limited availability constraints (chunk 253)
    Documentation Required

    specialty

    SP designation indicates specialty pharmacy handling and may be paired with LA (limited access); providers must comply with specialty distribution routes and any PA or QL rules associated with SP products.

    • Specialty (SP) designation appears alongside PA/QL/LA for many biologics and high‑cost agents (chunks 247, 252, 255)
    Documentation Required

    infusion center | office | specialty pharmacy

    Many specialty injectables and high‑cost agents are designated SP and/or LA, implying they must be dispensed through specialty pharmacy channels or administered at limited sites; verify site‑of‑care requirements and obtain PA as needed.

    • Examples: SKYTROFA, IMCIVREE, GATTEX list LA/PA/SP (chunks 137, 130, 200)
    Documentation Required

    infusion center

    Specialty products flagged 'SP' or 'LA' often require specialty pharmacy distribution or limited‑site administration; providers should coordinate with the payer and specialty pharmacy to meet authorization and dispensing requirements.

    • ADEMPAS, ambrisentan, JUXTAPID shown with LA/PA/SP (chunk 162)
    • Many agents designated SP require specialty distribution (chunks 251–252)
    Note
    Note
    Note
    Note
    Note
    Note

    Abbreviations and Definitions

    inv-113: PA — Prior Authorization (definitions)
    PAPrior Authorization — plan requires approval before the drug is filled; lack of approval may result in noncoverage.
    QLQuantity Limit — the plan limits the amount of drug that will be covered.
    STStep Therapy — the plan may require trials of preferred drugs before covering alternatives.
    inv-114: QL — Quantity Limit (definitions)
    QL (definition)Quantity Limit — the plan limits the amount of drug that will be covered (shown per formulation and time period).
    ExampleShown throughout the formulary as tablets/30 days, capsules/28 days, mLs/30 days, pens/28 days, etc.
    inv-115: ST — Step Therapy (definitions)
    ST (definition)Step Therapy — requires trying specified drugs first before coverage of alternatives; exceptions can be requested.
    Operational impactEntries flagged 'ST' may require documentation of prior trial/failure of preferred agents
    inv-116: SP — Specialty Drugs (definitions)
    SP (definition)Specialty Drugs — drugs that may require special handling, monitoring, or education and may be dispensed via specialty pharmacy.
    ImplicationSP flag often accompanies PA and QL for high‑cost biologic or specialty agents
    inv-117: Abbreviations for requirements/limits
    Common abbreviations — requirements/limitsPA = Prior Authorization; QL = Quantity Limit; LA = Limited Access; SP = Specialty Pharmacy; ACA = Access/ACA designation
    UsageThese abbreviations appear next to line items to indicate utilization management controls
    inv-121: ACA — ACA-related requirement/limit
    ACA flagACA — Affordable Care Act preventive coverage designation (appears for many vaccines and certain preventive drugs)
    OTC flagOTC — Over-the-counter designation that may affect coverage pathways for some insulins and smoking-cessation products
    inv-124: SP — Specialty (definition/implication)
    SP (specialty) indicatorSP indicates specialty pharmacy dispensing requirement or enrollment in a specialty program for certain high‑cost agents.
    Operational noteProducts marked SP typically require PA and additional documentation
    inv-138: OTC — Over-the-counter designation
    OTC designationOTC — Over-the-counter designation (e.g., some insulin products listed OTC) which may change coverage/claim routing),
    ExampleHUMULIN R and NOVOLIN R entries show OTC with QL for certain presentations
    inv-145: PA/LA/SP/FF — common requirement flags
    PA/LA/SP/FF abbreviationsPA = Prior Authorization; LA = Limited Access; SP = Specialty; FF = Frozen Formulary — appear together as requirement flags on many line items
    ImplicationWhen present, providers must follow listed authorization and dispensing processes to secure coverage

    Background and Scope

    Background: This formulary lists covered anti-infective agents, vaccines, specialty agents and many other drug classes with available strengths and formulations, and it indicates formulary tier placement and utilization management flags (such as PA, QL, ST, SP, LA, and formulary flags). The listing is intended to guide prescribing and dispensing by showing which products are covered and what management controls may apply.

    Biosimilar Listings

    Billing Rule

    adalimumab (HUMIRA)

    Multiple entries for adalimumab reference products and biosimilars are listed with PA, QL (commonly 2 pens/syringes per 28 days or 1 kit/180 days) and SP designation; prescribers must obtain PA and comply with QL and specialty pharmacy routing for these biologics.

    • ADALIMUMAB biosimilars show PA, QL, SP across kit and pen/syringe presentations (chunks 262–265, 270)